Hepatic Encephalopathy

New England Journal of Medicine

Volumn 313, Issue 14, 1985, Pages 865-873

  Fraser, Cosmo L ^a   Arieff, Allen I ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXOGLUTARIC ACID; ACTIVATED CARBON; AMINO ACID; AMPICILLIN; ANALGESIC AGENT; ASPARTIC ACID; BROMOCRIPTINE; DIURETIC AGENT; FATTY ACID; FRUCTOSE; GLUCOSE; GLUTAMINE; INFUSION FLUID; KAINIC ACID; KANAMYCIN; LACTOSE; LACTULOSE; LEVODOPA; MANNITOL; METRONIDAZOLE; NEOMYCIN; NEUROTRANSMITTER; OCTOPAMINE; SEDATIVE AGENT; SORBITOL; SULFANILAMIDE DERIVATIVE; TETRACYCLINE; TRANQUILIZER; TYRAMINE;

ADVERSE DRUG REACTION; ALCOHOL LIVER CIRRHOSIS; AMMONIA BLOOD LEVEL; BLOOD AND HEMOPOIETIC SYSTEM; BLOOD BRAIN BARRIER; BRAIN; BRAIN DISEASE; CENTRAL NERVOUS SYSTEM; DIARRHEA; DRUG THERAPY; HEPATIC COMA; HEPATIC ENCEPHALOPATHY; HEPATITIS; HUMAN; HYPERNATREMIA; HYPONATREMIA; INTOXICATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER; LIVER FAILURE; MYELINOLYSIS; ORAL DRUG ADMINISTRATION; OSMOSIS; PONS; PRIORITY JOURNAL; PROTEIN RESTRICTION; REVIEW; THERAPY;

EID: 0022259875     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198510033131406     Document Type: Review

References (147)

1. Adams RD, Foley JM. The neurological disorders associated with liver disease. Annu Rev Nerv Ment Dis Proc 1953; 32: 198.
2. Zieve L. The mechanism of hepatic coma. Hepatology 1981; 1: 360–5.
3. Horst D, Grace ND, Conn HO, et al. Comparison of dietary protein with an oral, branched chain-enriched amino acid supplement in chronic portal–systemic encephalopathy: a randomized controlled trial. Hepatology 1984; 4: 279–87.
4. Beaubernard C, Delorme M-L., Opolon P, et al. Effect of oral administration of branched chain amino acids on hepatic encephalopathy in the rat. Hepatology 1984; 4: 288–94.
5. Fischer JE, Baldessarini RJ. Pathogenesis and therapy of hepatic coma. Prog Liver Dis 1976; 5: 363–97.
6. Levy DE, Bates B, Caronna JJ, et al. Prognosis in nontraumatic coma. Ann Intern Med 1981; 94: 293–301.
7. Conn HO, Leevy CM, Vlahcevic ZR, et al. Comparison of lactulose and neomycin in the treatment of chronic portal–systemic encephalopathy: a double blind controlled trial. Gastroenterology 1977; 72: 573–83.
8. Wolpert E, Phillips SF, Summerskill WHJ. Ammonia production in the human colon: effects of cleansing, neomycin and acetohydroxamic acid. N Engl J Med 1970; 283: 159–64.
9. Plum F, Hindfelt B. The neurological complications of liver disease. In: Vinken PJ, Bruyn GW, eds. Handbook of clinical neurology. Vol. 27. Amsterdam: North Holland, 1976:349–77.
10. Hindfelt B, Plum F, Duffy TE. Effect of acute ammonia intoxication on cerebral metabolism in rats with portacaval shunts. J Clin Invest 1977; 59: 386–96.
11. Mutchnick MG, Lerner E, Conn HO. Portal–systemic encephalopathy and portacaval anastomosis: a prospective, controlled investigation. Gastroenterology 1974; 66: 1005–19.
12. McClain CJ, Zieve L, Doizaki WM, Gilberstadt S, Onstad GR. Blood methanethiol in alcoholic liver disease with and without hepatic encephalopathy. Gut 1980; 21: 318–23.
13. James JH, Ziparo V, Jeppsson B, Fischer JE. Hyperammonaemia, plasma aminoacid imbalance, and blood–brain aminoacid transport: a unified theory of portal–systemic encephalopathy. Lancet 1979; 2: 772–5.
14. Livingstone AS, Potvin M, Goresky CA, Finlayson MH, Hinchey EJ. Changes in the blood–brain barrier in hepatic coma after hepatectomy in the rat. Gastroenterology 1977; 73: 697–704.
15. Schafer DG, Jones EA. Potential neural mechanisms in the pathogenesis of hepatic encephalopathy. Prog Liver Dis 1982; 7: 615–27.
16. Ono J, Hutson DG, Dombro RS, Levi JU, Livingstone A, Zeppa R. Tryptophan and hepatic coma. Gastroenterology 1978; 74: 196–200.
17. Flannery DB, Hsia YE, Wolf B. Current status of hyperammonemia syndromes. Hepatology 1982; 2: 495–506.
18. Hilly MD, Romshe CA, Delamater P. Reye's syndrome and hyperaminoacidemia. J Pediatr 1974; 84: 362–5.
19. Campbell AGM, Rosenberg IE, Snodgrass PJ, Nuzum CT. Ornithine transcarbamylase deficiency: a cause of lethal neonatal hyperammonemia in males. N Engl J Med 1973; 288: 1–6.
20. Gabuzda GJ Jr, Phillips GB, Davidson CS. Reversible toxic manifestations in patients with cirrhosis of the liver given cation-exchange resins. N Engl J Med 1952; 246: 124–30.
21. Stahl J, Roger S, Witz J. Essai d'interprétation du mécanisme de l'épreuve d'hyperammoniémie provoquée chez les cirrhotiques. C R Soc Biol (Paris) 1952; 146: 1787–91.
22. Phillips GB, Schwartz R, Gabuzda GJ, Davidson CS. Syndrome of impending hepatic coma in patients with cirrhosis of liver given certain nitrogenous substances. N Engl J Med 1952; 247: 239–46.
23. Hoyumpa AM Jr, Desmond PV, Avant GR, Roberts RK, Schenker S. Hepatic encephalopathy. Gastroenterology 1979; 76: 184–95.
24. McDermott WV Jr. Metabolism and toxicity of ammonia. N Engl J Med 1957; 257: 1076–81.
25. Lockwood AH, McDonald JM, Reiman RE, et al. The dynamics of ammonia metabolism in man: effects of liver disease and hyperammonemia. J Clin Invest 1979; 63: 449–60.
26. Lockwood AH. Ammonia-induced encephalopathy. In: McCandless DW, ed. Cerebral energy metabolism and metabolic encephalopathy. New York: Plenum, 1985:203–28.
27. Marliss EB, Aoki TT, Pozefsky T, Most AS, Cahill GF Jr. Muscle and splanchnic glutamate metabolism in postabsorptive and starved man. J Clin Invest 1971; 50: 814–7.
28. Sherwin R, Joshi P, Hendler R, Felix P, Conn HO. Hyperglucagonemia in Laennec's cirrhosis: the role of portal–systemic shunting. N Engl J Med 1974; 290: 239–42.
29. Kamata S, Okada A, Watanabe T, Kawashima Y, Wada H. Effects of dietary amino acids on brain amino acids and transmitter amines in rats with a portacaval shunt. J Neurochem 1980; 35: 1190–9.
30. Rudman D, Galambos JT, Smith RB III, Salam AA, Warren WD. Comparison of the effect of various amino acids upon the blood ammonia concentration of patients with liver disease. Am J Clin Nutr 1973; 26: 916–25.
31. Weber FL, Veach GL. The importance of the small intestine in gut ammonium production in the fasting dog. Gastroenterology 1979; 77: 235–40.
32. Schalm SW, Van Der Mey T. Hyperammonemic coma after hepatectomy in germ-free rats. Gastroenterology 1979; 77: 231–4.
33. Nance FC, Batson RC, Kline DG. Ammonia production in germ-free Eck fistula dogs. Surgery 1971; 70: 169–74.
34. Munro HN, Fernstrom JD, Wurtman RJ. Insulin, plasma aminoacid imbalance, and hepatic coma. Lancet 1975; 1: 722–4.
35. Rosen HM, Yoshimura M, Hodgman JM, Fischer JE. Plasma amino acid patterns in hepatic encephalopathy of differing etiology. Gastroenterology 1977; 72: 483–7.
36. Strombeck DR, Rogers Q, Stern JS. Effects of intravenous ammonia infusion on plasma levels of amino acids, glucagon and insulin in dogs. Gastroenterology 1978; 74: 1165. abstract.
37. Hourani BT, Hamlin EM, Reynolds TB. Cerebrospinal fluid glutamine as a measure of hepatic encephalopathy. Arch Intem Med 1971; 127: 1033–6.
38. Munro HN, Femstrom JD, Wurtman RJ. Plasma neutral aminoacids and tryptophan in cirrhosis. Lancet 1975; 2: 419.
39. Chase RA, Davies M, Trewby PN, Silk DBA, Williams R. Plasma amino acid profiles in patients with fulminant hepatic failure treated by repeated polyacrylonitrile membrane hemodialysis. Gastroenterology 1978; 75: 1033–40.
40. Vergara F, Duffy TE, Plum F. α-Ketoglutaramate, a neurotoxic agent in hepatic coma. Trans Assoc Am Physicians 1973; 86: 255–63.
41. Gilon E, Szeinberg A, Tauman G, Bodonyi E. Glutamine estimation in cerebrospinal fluid in cases of liver cirrhosis and hepatic coma. J Lab Clin Med 1959; 53: 714–9.
42. Femstrom JD, Wurtman RJ. Elevation of plasma tryptophan by insulin in the rat. Metabolism 1972; 21: 337–42.
43. Bessman SP, Bessman AN. The cerebral and peripheral uptake of ammonia in liver disease with a hypothesis for the mechanisms of hepatic coma. J Clin Invest 1955; 34: 622–8.
44. Shorey J, McCandless DW, Schenker S. Cerebral α-ketoglutarate in ammonia intoxication. Gastroenterology 1967; 53: 706–11.
45. Hindfelt B, Siesjö BK. Cerebral effects of acute ammonia intoxication. II. The effect upon energy metabolism. Scand J Clin Lab Invest 1971, 28: 365–74.
46. Hirayama C. Tryptophan metabolism in liver disease. Clin Chim Acta 1971; 32: 191–7.
47. Ogihara K, Mozai T, Hirai S. Tryptophan as cause of hepatic coma. N Engl J Med 1966; 275: 1255–6.
48. Knell AJ, Davidson AR, Williams R, Kantamaneni BD, Curzon G. Dopamine and serotonin metabolism in hepatic encephalopathy. Br Med J 1974; 1: 549–51.
49. Condon RE. Effect of dietary protein on symptoms and survival in dogs with an Eck fistula. Am J Surg 1971; 121: 107–14.
50. Knell AJ, Pratt OE, Curzon G, Williams R. Changing ideas in hepatic encephalopathy. In: Neale G, ed. Eighth Symposium on Advanced Medicine. London: Pitman, 1972:156.
51. Woolley DW. The biochemical bases of psychoses, or the serotonin hypothesis about mental disease. New York: John Wiley, 1962.
52. Fischer JE. Hepatic coma in cirrhosis, portal hypertension, and following portacaval shunt: its etiologies and the current status of its treatment. Arch Surg 1974; 108: 325–36.
53. Curzon G, Kantamaneni BD, Winch J, Rojas-Bueno A, Murray-Lyon IM, Williams R. Plasma and brain tryptophan changes in experimental acute hepatic failure. J Neurochem 1973; 21: 137–46.
54. Cummings MG, James HJ, Setters PB. Regional brain study of indoleamine metabolism in the rat in acute hepatic failure. J Neurochem 1976; 27: 741–6.
55. Cummings MG, Soeters PB, James JH, Keane JM, Fischer JE. Regional brain indoleamine metabolism following chronic portacaval anastomosis in the rat. J Neurochem 1976; 27: 501–9.
56. Buxton BH, Stewart DA, Murray-Lyon IM, Curzon G, Williams R. Plasma amino acids in experimental acute hepatic failure and their relationship to brain tryptophan. Clin Sci Mol Med 1974; 46: 559–62.
57. Zieve L, Doizaki WM, Zieve FJ. Synergism between mercaptans and ammonia or fatty acids in the production of coma: a possible role for mercaptans in the pathogenesis of hepatic coma. J Lab Clin Med 1974; 83: 16–28.
58. Zieve L, Brunner G. Encephalopathy due to mercaptans and phenols. In: McCandless DW, ed. Cerebral energy metabolism and metabolic encephalopathy. New York: Plenum, 1985:179–202.
59. Foster D, Ahmed K, Zieve L. Action of methanethiol on Na+,K+ ATPase: implications for hepatic coma. Ann NY Acad Sci 1974; 242: 573–6.
60. Rossi-Fanelli F, Capocaccia L, Fischer JE. Correlation of plasma taurine levels with grades of hepatic encephalopathy in man. Gastroenterology 1977; 72: 1181. abstract.
61. Muto Y, Takahashi Y, Kawamura H. Effect of short-chain fatty acids on the electrical activity of neo-, paleo-, and archicortical system. Brain Nerve 1964; 16: 601–8.
62. Muto Y. Clinical study on the relationship of short-chain fatty acids and hepatic encephalopathy. Jpn J Gastroenterol 1966; 63: 19–23.
63. Samson FE Jr, Dahl N, Dahl DR. A study on the narcotic action of short chain fatty acids. J Clin Invest 1956; 35: 1291.
64. White RP, Samson FE Jr. Effects of fatty acid anions on the electroencephalogram of unanesthetized rabbits. Am J Physiol 1956; 186: 271–4.
65. Zieve L, Nicoloff DM, Mahadevan V. Effect of hepatectomy on volatile free fatty acids of the blood. Gastroenterology 1968; 54: 1285. abstract.
66. Zieve L. Encephalopathy due to short and medium chain fatty acids. In: McCandless DW, ed. Cerebral energy metabolism and metabolic encephalopathy. New York: Plenum, 1985:163–78.
67. Ahmed K, Thomas BS. The effects of long chain fatty acids on sodium plus potassium ion-stimulated adenosine triphosphatase of rat brain. J Biol Chem 1971; 246: 103–9.
68. Trauner DA. Regional cerebral NA+K+ ATPase activity following octanoate administration. Pediatr Res 1980; 14: 844–5.
69. Dahl DR. Short chain fatty acid inhibition of rat brain Na-K adenosine triphosphatase. J Neurochem 1968; 15: 815–20.
70. Knott PJ, Curzon G. Free tryptophan in plasma and brain tryptophan metabolism. Nature 1972; 239: 452–3.
71. Borg J, Warter JM, Schlienger JL, Imler M, Marescaux C, Mack G. Neurotransmitter modifications in human cerebrospinal fluid and serum during hepatic encephalopathy. J Neurol Sci 1982; 57: 343–56.
72. Matthews RJ, Roberts BJ. The effect of gamma-aminobutyric acid on synaptic transmission in autonomic ganglia. J Pharmacol Exp Ther 1961; 132: 19–22.
73. Kato E, Kuba K. Inhibition of transmitter release in bullfrog sympathetic ganglia induced by γ-aminobutytric acid. J Physiol 1980; 298: 271–83.
74. Schafer DF, Fowler JM, Jones EA. Colonic bacteria: a source of γ-aminobutyric acid in blood. Proc Soc Exp Biol Med 1981; 167: 301–3.
75. Fischer JE, Baldessarini RJ. False neurotransmitters and hepatic failure. Lancet 1971; 2: 75–80.
76. Roberts E. The γ-aminobutyric acid (GABA) system and hepatic encephalopathy. Hepatology 1984; 4: 342–5.
77. Roberts E, Krause DK. γ-Aminobutyric acid system in cardiovascular and cerebrovascular function. Isr J Med Sci 1982; 18: 75–81.
78. Jordan D, Poncet C, Veisseire M, Mornex R. Role of GABA in the control of thyrotropin secretion in the rat. Brain Res 1983; 268: 105–10.
79. Kawai K, Unger RH. Effects of γ-aminobutyric acid on insulin, glucagon, and somatostatin release from isolated perfused dog pancreas. Endocrinology 1983; 113: 111–3.
80. Mori A, Kosaka M. γ-Aminobutyric acid and its action on the adrenal cortex. 1. Effects of γ-aminobutyric acid on the ascorbic acid content of the adrenal gland. J Neurochem 1961; 7: 313–6.
81. Vincent SR, Hökfelt T, Wu J-Y. GABA neuron systems in hypothalamus and the pituitary gland: immunohistochemical demonstration using antibodies against glutamate decarboxylase. Neuroendocrinology 1982; 34: 117–25.
82. Schon F, Bean PM, Chapman D, Kelly JS. On GABA metabolism in the gliocyte cells of the rat pineal gland. Brain Res 1975; 85: 479–90.
83. Roberts E, Chase TN, Tower DB, eds. GABA in nervous system function. New York: Raven Press, 1976:554.
84. Roberts E, Lowe IP, Guth L, Jelinek B. Distribution of γ-aminobutyric acid and other amino acids in nervous tissue of various species. J Exp Zool 1958; 138: 313–28.
85. van Gelder NM, Elliott KAC. Disposition of yγ-aminobutyric acid administered to mammals. J Neurochem 1958; 3: 139–43.
86. Ferenci P, Pappas SC, Munson PJ, Henson K, Jones EA. Changes in the status of neurotransmitter receptors in rabbit model of hepatic encephalopathy. Hepatology 1984; 4: 186–91.
87. Moskowitz MA, Wurtman RJ. Catecholamines and neurological diseases. N Engl J Med 1975; 293: 274–80, 332–8.
88. Baldessarini RJ. Release of catecholamine: false neurotransmitter. In: Iversen LL, Iversen SD, Snyder SH, eds. Handbook of psychopharmacology. New York: Plenum, 1975:82–93.
89. Fischer JE, Baldessarini RJ. Neurotransmitter metabolism in hepatic encephalopathy. N Engl J Med 1975; 293: 1152–3.
90. Crossley IR, Wardle EN, Williams R. Biochemical mechanisms of hepatic encephalopathy. Clin Sci 1983; 64: 247–52.
91. Kuriyama K, Sze PY. Blood–brain barrier to H3-γ-aminobutyric acid in normal and amino oxyacetic acid-treated animals. Neuropharmacology 1971; 10: 103–8.
92. Ferenci P, Schafer DF, Shrager R, Jones EA. Metabolism of the inhibitory neurotransmitter γ-aminobutyric acid in a rabbit model of acute hepatic failure. Hepatology 1981; 1: 509. abstract.
93. Horowitz ME, Schafer DF, Molnar P, et al. Increased blood–brain transfer in a rabbit model of acute liver failure. Gastroenterology 1983; 84: 1003–11.
94. Victor M, Adams RD, Cole M. The acquired (non-Wilsonian) type of chronic hepatocerebral degeneration. Medicine (Baltimore) 1965; 44: 345–96.
95. Pilbeam CM, Anderson RM, Bhathal PS. The brain in experimental portal–systemic encephalopathy. II. Water and electrolyte changes. J Pathol 1983; 140: 347–55.
96. Hasson J, Leech RW. Experimental hepatocerebral disease: astrocytic changes in the globus pallidus of rats with carbon tetrachloride induced cirrhosis. Arch Pathol 1967; 84: 286–9.
97. Mossakowski MJ. Smialek M, Pronazsko A. Disturbances in the permeability of the cerebral blood vessels in experimental encephalopathy. Pol Med J 1971; 10: 208–7.
98. Norenberg MD, Lapham LW. The astrocyte response in experimental portal–systemic encephalopathy: an electron microscopic study. J Neuropathol Exp Neurol 1974; 33: 422.
99. Norenberg MD, Lapham LW, Nichols FA, May AG. An experimental model for the study of hepatic encephalopathy. Arch Neurol 1974; 31: 106–9.
100. Cavanagh JB, Kyu MH. Type II Alzheimer change experimentally produced in astrocytes in the rat. J Neurol Sci 1971; 12: 63–75.
101. Cavanagh JB, Lewis PD, Blakemore WF, Kyu MH. Changes in the cerebellar cortex in rats after portocaval anastomosis. J Neurol Sci 1972; 15: 13–26.
102. Ware AJ, D'Agostino AN, Combes B. Cerebral edema: a major complication of massive hepatic necrosis. Gastroenterology 1971; 61: 877–84.
103. Conn HO, Lieberthal MM. The hepatic coma syndromes and lactulose. Baltimore: Williams & Wilkins. 1979.
104. Losowsky MS, Scott BB. Ascites and oedema in liver disease. Br Med J 1973; 3: 336–8.
105. Trey C, Lipworth L, Chalmers TC, et al. Fulminant hepatic failure: presumable contribution of halothane. N Engl J Med 1968; 279: 798–801.
106. Williams R. Fulminant hepatic failure. Postgrad Med J 1983; 59 (Suppl 4):33–45.
107. Imler M, Schlienger J-L. The effect of chronic uremia on portal and systemic ammonemia in normal and portal-strictured rats. J Lab Clin Med 1979; 94: 872–8.
108. Schenker S, Breen KJ, Hoyumpa AM Jr. Hepatic encephalopathy: current status. Gastroenterology 1974; 66: 121–51.
109. Conn HO. Current diagnosis and treatment of hepatic coma. Hosp Pract 1973; 8(2):65–72.
110. Laidlaw J, Read AE. The E.E.G. in hepatic encephalopathy. Clin Sci 1963; 24: 109–20.
111. Pappas CS, Jones EA. Methods of assessing hepatic encephalopathy. Semin Liver Dis 1983; 3: 298–307.
112. Losowsky MS, Scott BB. Hepatic encephalopathy. Br Med J 1973; 3: 279–81.
113. Bircher J, Müller J, Guggenheim P, Haemmerli UP, Treatment of chronic portal–systemic encephalopathy with lactulose. Lancet 1966; 1: 890–3.
114. Dahlqvist A, Gryboski JD. Inability of the human small-intestinal lactase to hydrolyze lactulose. Biochim Biophys Acta 1965; 110: 635–6.
115. Bircher J, Haemmerli UP, Trabert E, Largiader F, Mocetti T. The mechanism of action of lactulose in portal–systemic encephalopathy: non-ionic diffusion of ammonia in the canine colon. Rev Fr Etud Clin Biol 1971; 16: 352–7.
116. Castell DO, Moore EW. Ammonia absorption from the human colon: the role of nonionic diffusion. Gastroenterology 1971; 60: 33–42.
117. Meyers S, Lieber CS. Reduction of gastric ammonia by ampicillin in normal and azotemic subjects. Gastroenterology 1976; 70: 244–7.
118. Dawson AM, McLaren J, Sherlock S. Neomycin in the treatment of hepatic coma. Lancet 1957, 2: 1263–8.
119. Fischer CJ, Faloon WW. Blood ammonia levels in hepatic cirrhosis: their control by oral administration of neomycin. N Engl J Med 1957; 256: 1030–5.
120. Fast BB, Wolfe SJ, Stormont JM, Davidson CS. Antibiotic therapy in the management of hepatic coma. Arch Intern Med 1958; 101: 467–75.
121. Orlandi F, Freddara U, Candelaresi MT, et al. Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy: a randomized clinical study. Dig Dis Sci 1981; 26: 498–506.
122. Crossley IR, Williams R. Progress in treatment of chronic portasystemic encephalopathy. Gut 1984; 25: 85–98.
123. Bennett WM, Kieffe E, Melnyk G, Mahler D, Rösch J, Porter GA. Response to dopamine hydrochloride in the hepatorenal syndrome. Arch Intern Med 1975; 135: 964–71.
124. Canalese J, Gimson AES, Davis C, Mellon PJ, Davis M, Williams R. Control trial of dexamethasone and mannitol for cerebral oedema of fulminant hepatic failure. Gut 1982; 23: 625–9.
125. Dienst SG. Treatment of progressive ammonia intoxication by exclusion of the colon. N Engl J Med 1964; 270: 555–6.
126. Hume HA, Erb WH, Stevens LW, Hallahan JD. Treatment of hepatic encephalopathy by surgical exclusion of the colon. JAMA 1966; 196: 593–4.
127. Gelfand ML, Sussman L, Caimol BC, Florita C, Joson F. Successful treatment of hepatic coma by exchange transfusion. JAMA 1967; 201: 630–3.
128. Berger RL, Stanton JR, Liversage RM Jr, McGoldrick DM, Graham JH, Stohlman F Jr. Blood exchange in the treatment of hepatic coma. JAMA 1967; 202: 267–74.
129. Trey C, Burns D, Saunders SJ. Treatment of hepatic coma by exchange blood transfusion. N Engl J Med 1966; 274: 473–81.
130. Sabin S, Merritt JA. Treatment of hepatic coma in cirrhosis by plasmapheresis and plasma infusion (plasma exchange). Ann Intern Med 1968; 68: 1–7.
131. Hollander D, Kiebankoff G, Osteen RT. Human-baboon cross-circulation for treatment of hepatic coma. JAMA 1971; 218: 67–71.
132. Summers RW, Curtis SJ, Hartford CE, Rubush JL. Acute hepatic coma treated by cross circulation with irreversibly comatose donor. JAMA 1970; 214: 2297–301.
133. Gazzard BG, Portmann B, Weston MJ, et al. Charcoal haemoperfusion in the treatment of fulminant hepatic failure. Lancet 1974; 1: 1301–7.
134. Norenberg MD, Leslie KO, Robertson AS. Association between rise in serum sodium and central pontine myelinolysis. Ann Neurol 1982; 11: 128–35.
135. Warren SE, Mitas JA II, Swerdlin A. Hypernatremia in hepatic failure. JAMA 1980; 243: 1257–60.
136. Wilkinson SP, Blendis LM, Williams R. Frequency and type of renal and electrolyte disorders in fulminant hepatic failure. Br Med J 1974; 1: 186–9.
137. Nelson DC. McGrew WRG Jr, Hoyumpa AM Jr. Hypernatremia and lactulose therapy. JAMA 1983; 249: 1295–8.
138. Kaupke C, Sprague T, Gitnick GL. Hypernatremia after the administration or lactulose. Ann Intern Med 1977; 86: 745–6.
139. Arieff AI. Effects of water, electrolyte and acid–base disorders on the central nervous system. In: Arieff AI, DeFronzo RA, eds. Fluid, electrolyte and acid–base disorders. New York: Churchill Livingstone, 1985:969–1040.
140. Adams RD, Victor M, Mancall EL. Central pontine myelinolysis: a hitherto undescribed disease occurring in alcoholic and malnourished patients. Arch Neurol Psychiatry 1959; 81: 154–72.
141. Burear PJ, Norenberg MD, Yarnell PR. Hyponatremia and central pontine myelinolysis. Neurology (Minneap) 1977; 27: 223–6.
142. Tihen WS. Central pontine myelinolysis and Rosenthal fibers of the brain-stem: association with emaciation and prolonged intravenous hypcralimentation. Neurology (Minneap) 1972; 22: 710–6.
143. Fraser CL, Arieff AI. Symptomatic hyponatremia: management and relation to central pontine myelinolysis, Semin Neurol 1984; 4: 445–52.
144. Ayus JC, Krothapalli R, Arieff AI, Frommer JP., Overcorrection rather than rapid correction induces central pontine myelinolysis in patients with severe hyponatremia. Kidney Int 1985; 27: 132. abstract.
145. Thompson DS, Hutton JT, Stears JC, Sung JH, Norenberg M. Computerized tomography in the diagnosis of central and extrapontine myelinolysis. Arch Neurol 1981; 38: 243–6.
146. DeWitt LB, Buonanno FS, Kistler JP. Central pontine myelinolysis: demonstration by nuclear magnetic resonance. Neurology (NY) 1984; 34: 570–6.
147. Zucharczyk W, Brant-Zawadzki M, Norman D, Newton TH. Magnetic resonance imaging of the central nervous system: an update. West J Med 1985; 142: 54–62.